Learning objectives
The reader should be able to distinguish acute tubulointerstitial nephritis from acute tubular injury, obstruction, infection, and glomerular disease; recognize drug-, immune-, infectious-, metabolic-, and genetic causes; interpret tubular electrolyte and acid–base defects; decide when biopsy is needed; use corticosteroids selectively in ATIN; and manage chronic tubulointerstitial disease and its CKD complications.
19.1 Clinical framework
Tubulointerstitial diseases primarily injure tubular epithelium and interstitium, but the clinical phenotype depends on cause, tempo, and severity. Acute tubulointerstitial nephritis (ATIN) is an inflammatory AKI syndrome. Chronic tubulointerstitial disease produces impaired concentration, salt handling, acidification, potassium balance, and progressive fibrosis. The same patient may have multiple contributors, including medications, infection, obstruction, hemodynamic AKI, and CKD.
19.2 Acute tubulointerstitial nephritis
Drug-associated ATIN is common, with antibiotics, proton-pump inhibitors, NSAIDs, immune checkpoint inhibitors, diuretics, and other agents implicated. The fever–rash–eosinophilia triad is uncommon; its absence does not exclude ATIN. Sterile pyuria, WBC casts, mild proteinuria, hematuria, and eosinophilia may occur, but none is diagnostic. Nephrotic-range proteinuria is unusual except in NSAID-associated disease or concurrent glomerular pathology.
The differential includes acute tubular injury, pyelonephritis, obstruction, renal infarction, AAV, lupus nephritis, infection-related GN, TMA, and crystal nephropathy. Eosinophiluria is neither sufficiently sensitive nor specific to confirm ATIN. Fractional excretion of sodium is influenced by diuretics, CKD, sepsis, and volume status and should not be used as an ATIN diagnostic test.
19.3 Chronic tubulointerstitial disease
Chronic disease results from persistent medication exposure, reflux or obstruction, analgesic nephropathy, lithium, calcineurin inhibitors, heavy metals, aristolochic acid, metabolic disorders, hypercalcemia, hypokalemia, urate disorders, autoimmune disease, IgG4-related disease, sarcoidosis, and inherited disorders. Polyuria, nocturia, low urine specific gravity, salt wasting, hyperchloremic metabolic acidosis, hypokalemia, or disproportionate anemia can be clues. Small scarred kidneys suggest chronicity, but normal kidney size does not exclude substantial disease.
19.4 Diagnostic approach
Start with a meticulous medication and exposure timeline, including over-the-counter agents, herbal products, antibiotics, PPIs, NSAIDs, immune therapies, contrast, occupational exposure, and recent infections. Review baseline creatinine, urinalysis, blood pressure, volume status, rash, fever, arthralgia, sicca symptoms, uveitis, pulmonary disease, and obstructive symptoms.
Obtain serum creatinine/eGFR, electrolytes, bicarbonate, magnesium, phosphate, urinalysis with microscopy, ACR/PCR, CBC, and renal ultrasound when obstruction or structural disease is possible. Depending on context, test ANA, ANCA, complements, anti-GBM, hepatitis, HIV, IgG4, calcium, uric acid, SPEP/free light chains, and cultures. Fractional excretion indices may describe tubular handling but rarely establish the diagnosis.
Kidney biopsy is the reference standard when the diagnosis is uncertain, kidney function is severely impaired, the suspected drug cannot be stopped safely, the response is atypical, or immunosuppression is being considered. Pathology may show interstitial edema, lymphocytes, plasma cells, eosinophils, tubulitis, granulomas, crystals, or chronic interstitial fibrosis and tubular atrophy.
| Finding | Supports but does not prove | Important limitation |
|---|---|---|
| Sterile pyuria or WBC casts | ATIN, infection, interstitial inflammation | May be absent; can occur in other diseases |
| Eosinophiluria | Possible drug-related interstitial inflammation | Poor sensitivity and specificity |
| Fever/rash/eosinophilia | Hypersensitivity phenotype | Classic triad occurs in a minority |
| FENa above 1% | Tubular or intrinsic AKI | Not diagnostic; affected by diuretics and CKD |
| Enlarged or normal kidneys | Acute interstitial edema | Ultrasound is nonspecific |
| Interstitial fibrosis/tubular atrophy | Chronic damage and limited recovery | Requires clinicopathologic context |
19.5 Management of ATIN
Immediately discontinue the suspected culprit when clinically feasible and substitute a safer agent. Exclude obstruction, infection, hemodynamic causes, crystal disease, and glomerular disease. Provide supportive AKI care, including volume assessment, electrolyte and acid–base management, medication dose adjustment, and dialysis for standard indications.
Corticosteroids are considered in significant or non-improving ATIN after removal of the culprit and exclusion of active infection. Observational evidence and contemporary reviews favor earlier treatment in selected patients with biopsy-supported or strongly suspected inflammatory ATIN, but dose and duration should be individualized. A common specialist approach is prednisone 0.5–1 mg/kg/day followed by a taper, with lower exposure in mild disease and careful monitoring for infection, diabetes, bone disease, and psychiatric toxicity. Steroids are not automatic for every creatinine rise and should not be used to mask untreated infection or obstruction.
Immune checkpoint inhibitor-associated ATIN requires coordination with oncology; decisions about holding or rechallenging therapy depend on AKI grade, competing cancer benefit, biopsy information, response, and recurrence risk.
19.6 Chronic disease and tubular defects
Management is cause-directed: relieve obstruction, treat infection, stop nephrotoxins, manage sarcoidosis or IgG4-related disease, correct hypercalcemia or hypokalemia, and address inherited disorders. Type 1 distal RTA produces impaired urinary acidification and often hypokalemia; type 2 proximal RTA may occur with Fanconi syndrome; type 4 RTA is characterized by hyperkalemia and reduced ammonium excretion. Treatment should be based on serum and urine data, not assumed from a diagnostic label.
Use sodium bicarbonate or potassium citrate when indicated, replace potassium and magnesium carefully, manage bone disease, monitor blood pressure and albuminuria, and apply CKD risk-reduction measures. Progression is driven by the cause and the extent of fibrosis; chronic tubulointerstitial disease does not inevitably progress to ESRD if the cause is removed early.
Clinical pearls
- The fever–rash–eosinophilia triad is uncommon in ATIN.
- Eosinophiluria does not diagnose ATIN.
- FENa is not an ATIN test.
- Drug withdrawal is the first treatment step.
- Biopsy is valuable when immunosuppression or diagnostic uncertainty is present.
- Nephrotic proteinuria suggests NSAID-associated disease or a concurrent glomerular lesion.
- The degree of interstitial fibrosis and tubular atrophy is a major prognostic marker.
- Chronic tubular dysfunction can produce clinically important RTA, potassium, magnesium, and phosphate disorders.
| Finding | What it may support | Important limitation |
|---|---|---|
| Sterile pyuria/WBC casts | ATIN or interstitial inflammation | May be absent and occurs in infection or other diseases |
| Eosinophiluria | Possible drug-associated ATIN | Poor sensitivity and specificity |
| FENa >1% | Intrinsic tubular or interstitial AKI | Not diagnostic; altered by diuretics and CKD |
| Fibrosis/tubular atrophy | Chronic damage | Requires clinicopathologic context |
Summary
Tubulointerstitial disease is a diverse group of acute and chronic disorders. ATIN is a clinical–pathologic diagnosis in which medication withdrawal and exclusion of mimics are central. Steroids may benefit selected inflammatory cases but are not automatic. Chronic disease requires cause-directed therapy and careful management of concentrating defects, RTA, potassium and magnesium disorders, CKD, and fibrosis.
Question 1
Which statement about eosinophiluria is correct?
A. It confirms ATIN. B. It excludes pyelonephritis. C. It is neither sensitive nor specific for ATIN. D. It is required before steroids.
Answer: C. Eosinophiluria may support suspicion but cannot establish the diagnosis.
Question 2
What is the first intervention in suspected drug-induced ATIN?
A. Immediate cyclophosphamide B. Stop the suspected culprit when feasible C. Start dialysis in all cases D. Restrict all fluids
Answer: B. Removing the trigger is the key initial step.
Question 3
When is biopsy most useful?
A. In every mild AKI B. When diagnosis is uncertain or immunosuppression is being considered C. Only after ESRD develops D. Never if pyuria is present
Answer: B. Biopsy clarifies diagnosis and treatment when the result will change management.
Question 4
Which feature should prompt consideration of a concurrent glomerular lesion?
A. Mild proteinuria B. Nephrotic-range proteinuria C. Low urine specific gravity D. Mild hyperchloremic acidosis
Answer: B. Nephrotic proteinuria is atypical for most ATIN.
Question 5
Which RTA pattern is characterized by hyperkalemia?
A. Type 1 distal RTA only B. Type 2 proximal RTA only C. Type 4 RTA D. No RTA pattern
Answer: C. Type 4 RTA reflects impaired ammonium excretion and hypoaldosterone physiology.
Question 6
What is the major pathologic determinant of limited recovery in chronic tubulointerstitial disease?
A. Eosinophiluria B. Interstitial fibrosis and tubular atrophy C. Fever D. Urine pH alone
Answer: B. Fibrosis and tubular atrophy reflect chronic irreversible injury.